Abstract:Background Systemic lupus erythematosus (SLE) patients exist an imbalance between CD4+CD25+FoxP3+ T regulatory (Treg) and IL-17-producing cells (Th17). Correction of this Treg/Th17 imbalance may have therapeutic impact for SLE patients. Our previous study demonstrated that bone marrow derived mesenchymal stem cells (BMSCs) from SLE patients are defective in immune modulation, which might be involved in Treg/Th17 imbalance and disease onset, but the mechanisms are not clear yet. The expression imbalance of microRNAs (miRNAs) can cause cell dysfunction, which participates in a variety of diseases development. As an important computer predicted target of let-7, interlukin-6 (IL-6) is an important negative immune regulatory factors secreted by BMSCs. Our previous experiments found that the expressions of let-7 are markedly down-regulated in SLE BMSCs by microRNA array analysis, and the synthesis of IL-6 is significantly higher in SLE BMSCs compared to normal controls. Objectives To investigate whether loss of let-7 could play its role in SLE BMSCs immune modulation defects by directly up-regulating IL-6 mRNA, which might contribute to Treg/Th17 imbalance in PBMCs from SLE patients, to further understand the pathogenesis of SLE. Methods BMSCs were isolated, cultured and expanded from iliac crest bone marrow of four healthy donors and four SLE patients. Real-time PCR was used to further determine the let-7 expression and IL-6 mRNA level in BMSCs from healthy controls and SLE patients. The important computer predicted target of let-7, IL-6 was determined using the luciferase reporter assay. Let-7-mimics, let-7-inhibitor, and let-7-negative control were transfected to BMSCs with using Lipofectamine 2000. BMSCs from healthy controls and SLE patients were co-cultured with PBMCs from SLE patients for 72 hours to detect their effect on the ratio of Treg/Th17. Results Compared to normal controls, the expression of let-7 was markedly down-regulated in BMSCs from SLE patients by RT-PCR, and the synthesis of IL-6 mRNA and protein levels were significantly higher in BMSCs from SLE patients. Compared to let-7-negative controls, transfection of BMSCs with let-7-mimics markedly lower synthesis of TGF-β1 mRNA, and let-7-inhibitor led to an opposite effect. The mean value of Treg/Th17 was significantly decreased in PBMCs from SLE patients compared to normal controls. Transfection of normal BMSCs with let-7-inhibitor caused significant downregulation of Treg/Th17 compared to let-7-negative controls, while transfection with let-7-mimics led to an opposite effect. Conclusions SLE patients exist an imbalance between Treg and Th17 cells, which might be associated with up-regulation of IL-6 secretion of BMSCs by loss of let-7. Disclosure of Interest None declared

THU0050 Leptin and Neutrophil Activating Protein 2 Promote Mesenchymal Stem Cells Senescence Through the Activation of Pi3k/Akt Pathway in Systemic Lupus Erythematosus

Leptin and Neutrophil‐Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3‐kinase/akt Pathway in Patients with Systemic Lupus Erythematosus

Enhanced Apoptosis And Senescence Of Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus

Effect of sera from SLE patients on senescence of bone marrow-derived mesenchymal stem cells and its mechanism

The Supernatant of Bone Marrow from SLE Patients Promotes the Senescence of Mesenchymal Stem Cells

Study of leptin-treated mesenchymal stem cells modulate subsets of immune cells

The effects of leptin on the senescence of bone marrow-derived mesenchymal stem cells, frequencies of immune cells and lupus disease in MRL/Ipr mice

Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop

High Level of Reactive Oxygen Species Impaired Mesenchymal Stem Cell Migration Via Overpolymerization of F-actin Cytoskeleton in Systemic Lupus Erythematosus

Circulating Exosomes Derived-miR-146a from Systemic Lupus Erythematosus Patients Regulates Senescence of Mesenchymal Stem Cells

Association of bone marrow mesenchymal stem cells and intracellular reactive oxygen species levels in patients with systemic lupus erythematosus

Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis.

Mesenchymal Stem Cells Attenuate Systemic Lupus Erythematosus by Inhibiting NLRP3 Inflammasome Activation Through Pim-1 Kinase.

Mesenchymal Stem Cell Transplantation Alleviated Atherosclerosis in Systemic Lupus Erythematosus Through Reducing MDSCs

AB0045 MESENCHYMAL STEM CELLS INHIBIT THE ACTIVATED COMPLEMENT C5 BY CLUSTERIN IN LUPUS NEPHRITIS

Mesenchymal Stem Cells Prevent Podocyte Injury in Lupus-Prone B6.MRL-Faslpr Mice Via Polarizing Macrophage into an Anti-Inflammatory Phenotype

UP-REGULATION OF ENDOGENOUS LEPTIN IMPROVES HUMAN MESENCHYMAL STEM CELL SURVIVAL ABILITY IN VITRO AND THIS CELLS PROTECT FATAL CARDIAL MYOCYTES FROM APOPTOSIS

AB0160 Loss of Let-7 Microrna Upregulates Il-6 in Bone Marrow-Derived Mesenchymal Stem Cells Triggering Treg/th17 Imbalance in Patients with Systemic Lupus Erythematosus

An unbiased proteomics approach to identify the senescence-associated secretory phenotype of human bone marrow-derived mesenchymal stem cells

Overexpression of miR-20a-5p in mesenchymal stem cell derived-exosomes from systemic lupus erythematosus patients restored therapeutic effect and Treg immune regulation

Paracrine Senescence of Mesenchymal Stromal Cells Involves Inflammatory Cytokines and the NF-κB Pathway